Literature DB >> 9128996

Diagnostic workup of patients with suspected pancreatic carcinoma: the University of California-Los Angeles approach.

B Gloor1, K E Todd, H A Reber.   

Abstract

BACKGROUND: A large number of diagnostic procedures (e.g., ultrasound, computed tomography [CT] scan, fine-needle aspiration [FNA], angiography, endoscopic retrograde cholangiopancreatography [ERCP], and laparoscopy), are available to the clinician as he/she pursues the workup of patients who are thought to have a pancreatic (periampullary) malignancy. Not all of these procedures should be used in every patient and some have been overused.
METHODS: Based on a current literature review and their own experience, the authors describe the rationale of the diagnostic workup in patients with suspected pancreatic carcinoma in a single institution (a university medical center).
RESULTS: Helical CT scan provides the best overall assessment of patients with periampullary malignancies, and it is often the only test required. If the patient's history and blood test abnormalities suggest pancreatic carcinoma and the helical CT scan shows a mass in the head of the pancreas that appears to be resectable, the patient should be prepared for surgery. If no mass is apparent on the helical CT scan, a diagnostic ERCP is indicated. If microscopic proof of the diagnosis will avoid surgery, then an FNA for cytology should be performed. When unresectability appears likely and cannot be confirmed in less invasive ways, laparoscopy is indicated.
CONCLUSIONS: In patients with periampullary malignancies, helical CT scan provides the best overall assessment. Guidelines are presented for the selective use of ultrasound, FNA, ERCP, and laparoscopy, which are important for the most cost-effective workup of these patients.

Entities:  

Mesh:

Year:  1997        PMID: 9128996     DOI: 10.1002/(sici)1097-0142(19970501)79:9<1780::aid-cncr21>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  The impact of laparoscopic biopsy of pancreatic lymph nodes with helium and carbon dioxide on port site and liver metastasis in BOP-induced pancreatic cancer in hamster.

Authors:  F A Wenger; C A Jacobi; M Kilian; H Dressler; H Guski; J M Müller
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Validity of the hospital discharge diagnosis in epidemiologic studies of biliopancreatic pathology. PANKRAS II Study Group.

Authors:  M Porta; S Costafreda; N Malats; L Guarner; M Soler; J M Gubern; E García-Olivares; M Andreu; A Salas; J M Corominas; J Alguacil; A Carrato; J Rifà; F X Real
Journal:  Eur J Epidemiol       Date:  2000-06       Impact factor: 8.082

3.  Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma?

Authors:  Margo Shoup; Corinne Winston; Murray F Brennan; Diane Bassman; Kevin C Conlon
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

4.  Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis.

Authors:  R J Bold; C Charnsangavej; K R Cleary; M Jennings; A Madray; S D Leach; J L Abbruzzese; P W Pisters; J E Lee; D B Evans
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

5.  Utilization of preoperative endoscopic ultrasound for pancreatic adenocarcinoma.

Authors:  Ryan K Schmocker; David J Vanness; Caprice C Greenberg; Jeff A Havlena; Noelle K LoConte; Jennifer M Weiss; Heather B Neuman; Glen Leverson; Maureen A Smith; Emily R Winslow
Journal:  HPB (Oxford)       Date:  2017-02-23       Impact factor: 3.647

6.  Diagnostic laparoscopy.

Authors:  T E Udwadia
Journal:  Surg Endosc       Date:  2003-09-10       Impact factor: 4.584

7.  K-ras gene mutation in the diagnosis of ultrasound guided fine-needle biopsy of pancreatic masses.

Authors:  Min Zheng; Lian-Xin Liu; An-Long Zhu; Shu-Yi Qi; Hong-Chi Jiang; Zhu-Ying Xiao
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.